Article
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.
Cancer discovery - 6 Feb 2023
Kemp Samantha B, Cheng Noah, Markosyan Nune, Sor Rina, Kim Il-Kyu, Hallin Jill, Shoush Jason, Quinones Liz, Brown Natalie V, Bassett Jared B, Joshi Nikhil, Yuan Salina, Smith Molly, Vostrejs William P, Perez-Vale Kia Z, Kahn Benjamin, Mo Feiyan, Donahue Timothy R, Radu Caius G, Clendenin Cynthia, Christensen James G, Vonderheide Robert H, Stanger Ben Z
Abstract excerpt
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.